There has been a 30-fold increase in dengue cases in the past 50 years, and there is strong need for better, faster and more efficient dengue diagnostics technological solutions.
€10M (Round C) will be used for setup large scale manufacturing line in Asia and push commercialization in the target countries
Denmark offers state-of-the-art high-quality biotech environment. The Company combines top-class European biochemistry with hardware and software development in Asia.
Winner of the $875,000 global healthcare Challenge (900+ challengers), and “Global Winner” of $100,000 Global-Entrepreneurship-Summit as the most impactful technology for South East Asia (1,700+ challengers).
About Management Team
The core management team has a strong scientific background and an innovative, commercial thinking.
About Our Product
Our main product is a portable (<3kg) optical reader based on Blu-ray technology components, a portable laboratory device which can run the same diagnostics accuracy of large equipment, compacted into a user-friendly and affordable unit.
One-drop-of-blood quantitative blood POCT testing technology. Technology based on a reader, and single-use blood test cartridges, developed to quickly diagnose different viruses.
The current dengue diagnostics market is approx. €300M/year, but the potential is more than €1.8B/year. Asia accounts for 40%, and LATAM for 45% (15% between Australia and Africa). The disease is now endemic in more than 100 countries including China. The global infectious diseases IVD market is approx. €35B in 2016.
The Company raised €6.9M from private sources and €1.9M from grants (non-diluting financing), totaling €8.8M in the last 3.5 years.
The market of dengue diagnostics is dominated by Alere (recently acquired by Abbott for €5B) through both their Panbio and Standard Diagnostic (SD) product lines, available in ELISA and RDTs formats.
Available to be discussed with registered investors
Disclosure: Investing in startups carries a high degree of risk. In general, financial and operating risks confronting both early and developmental-stage companies, as well as more mature expansion-stage companies are significant. Many emerging growth companies go out of businesses every year. It is difficult to know how companies will grow, if at all, or what changes may occur in the market. A loss of an investors entire investment is possible and no profit may be realized. Investors are responsible for conducting their own due diligence.
* It should not be assumed that recommendations made in the future will be profitable or will equal the performance of securities in this list